Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma

BACKGROUND: Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with new combination therapies demonstrating improved response rates and survival. There are no head-to-head prospective trials comparing an immunotherapy doublet with an immunotherapy/tyrosine-kinase inhibitor-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarrabi, Kevin K, Handorf, Elizabeth, Miron, Benjamin, Zibelman, Matthew R, Anari, Fern, Ghatalia, Pooja, Plimack, Elizabeth R, Geynisman, Daniel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907035/
https://www.ncbi.nlm.nih.gov/pubmed/36200791
http://dx.doi.org/10.1093/oncolo/oyac195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907035/
https://www.ncbi.nlm.nih.gov/pubmed/36200791
http://dx.doi.org/10.1093/oncolo/oyac195

Ejemplares similares